10-K: Outlook Therapeutics Reports Fiscal Year 2024 Results, Awaits Key Clinical Data for ONS-5010/LYTENAVA

Outlook Therapeutics reports its fiscal year 2024 results, highlighting the European approval of ONS-5010/LYTENAVA and ongoing efforts to secure U.S. approval, while also addressing financial challenges and a recent workforce reduction.

Summary

• Outlook Therapeutics has released its fiscal year 2024 results, showing a net loss of $75.4 million, compared to a net loss of $59.0 million in the previous year.
• The company has not generated any revenue from product sales, and its success is heavily dependent on the commercialization of ONS-5010/LYTENAVA.
• ONS-5010/LYTENAVA has received marketing authorization in the EU and UK for the treatment of wet AMD, with initial commercial launches anticipated in the first half of calendar 2025.
• The company is working to resubmit its BLA for ONS-5010/LYTENAVA to the FDA in the first quarter of calendar 2025, following the completion of the NORSE EIGHT clinical trial.
• The NORSE EIGHT trial did not meet its pre-specified non-inferiority endpoint at week 8, but preliminary data showed improvement in vision and biologic activity.
• The company has reduced its workforce by 23% to reduce operating expenses and preserve capital.
• There is substantial doubt about the company's ability to continue as a going concern, and it will need to raise substantial additional funding to support its operations.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as the EU and UK approvals for ONS-5010/LYTENAVA, the company faces significant financial challenges, a failed primary endpoint in a key clinical trial, and a workforce reduction. The overall sentiment is cautious and somewhat negative due to the financial uncertainties and regulatory hurdles.

Positives

• ONS-5010/LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU and UK.
• The company has a strategic collaboration agreement with Cencora to support the commercial launch of ONS-5010/LYTENAVA in Europe and the United States.
• The company has received agreement from the FDA on three SPAs for three additional registration clinical trials for ONS-5010/LYTENAVA to treat BRVO and DME.

Negatives

• The company has incurred significant losses and negative cash flows from operations since its inception.
• The company has never generated any revenue from product sales.
• The NORSE EIGHT trial did not meet its pre-specified non-inferiority endpoint at week 8.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has reduced its workforce by 23% to reduce operating expenses.

Risks

• The company is highly dependent on the success of ONS-5010/LYTENAVA, and failure to obtain regulatory approval outside the EU and UK or to successfully commercialize it would harm the business.
• The company may need to raise substantial additional funding, which may not be available on acceptable terms or at all.
• Clinical drug development is a lengthy and expensive process, and the company may encounter substantial delays or fail to demonstrate safety and efficacy.
• The company faces intense competition and rapid technological change, and competitors may develop therapies that are more advanced or effective.
• The company currently has no marketing and sales organization and may be unable to establish and maintain sales and marketing capabilities.
• The company relies on third parties for manufacturing and testing, and failure of these third parties to perform could harm the business.
• The company may become involved in lawsuits to protect or enforce patents, which could be expensive and time-consuming.
• The company may be subject to claims that its employees have wrongfully used or disclosed confidential information of third parties.
• The company may be subject to claims that its employees have wrongfully used or disclosed alleged trade secrets of their former employers.
• The company may be subject to claims challenging the inventorship of its patent filings and other intellectual property.
• The company may be subject to claims that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that its employees have wrongfully used or disclosed alleged trade secrets of their former employers.
• The company may not be able to protect its intellectual property rights throughout the world.
• The company may not be successful in obtaining or maintaining necessary rights to ONS-5010/LYTENAVA or its product candidates through acquisitions and in-licenses.
• Unfavorable global economic and political conditions could adversely affect the company's business, financial condition or results of operations.
• The company is highly dependent on the services of its key executives and personnel, and if it is not able to retain these members of its management or recruit additional management, clinical and scientific personnel, its business will suffer.
• The company and certain of its officers have been named as defendants in a pending securities class action lawsuit and a shareholder derivative action.
• If the company's information technology systems or data, or those of third parties upon which it relies, are or were compromised, it could experience adverse consequences.
• The trading price of the company's securities is likely to be volatile, and purchasers of its securities could incur substantial losses.
• GMS Ventures beneficially owns a significant percentage of the company's common stock and has the right to designate members of its board of directors and is able to exert significant control over matters subject to stockholder approval.

Future Outlook

The company plans to resubmit its BLA for ONS-5010/LYTENAVA to the FDA in the first quarter of calendar 2025 and anticipates commencing initial commercial launches in the EEA and UK in the first half of calendar 2025. The company also plans to develop ONS-5010/LYTENAVA for use in the treatment of other retina diseases such as DME and BRVO.

Management Comments

• The company is working to address the open CMC items and has concluded a series of Type C and Type D meetings with the FDA to help to resolve these comments prior to reporting top line results from NORSE EIGHT in the fourth quarter of calendar 2024.
• The company is currently assessing options to commercialize ONS-5010/LYTENAVA either directly or through a strategic partner outside of the United States.

Industry Context

The document highlights the competitive landscape in the ophthalmic drug market, particularly for wet AMD treatments, where multiple branded drugs and biosimilars are available. The company aims to position ONS-5010/LYTENAVA as a lower-cost alternative to these options, while also mitigating the risks associated with off-label use of repackaged bevacizumab.

Comparison to Industry Standards

• The document mentions several competitors in the wet AMD market, including Novartis (LUCENTIS, BEOVU), Regeneron (EYLEA), Genentech (VABYSMO), and biosimilar versions of LUCENTIS and EYLEA from Biogen, Coherus and Amgen.
• The company aims to compete with these established players by offering a lower-cost alternative to biosimilars and premium branded products, while being priced higher than off-label compounds.
• The document notes that 66.3% of new patient starts in the U.S. are off-label repackaged bevacizumab, indicating a significant market opportunity for an approved ophthalmic formulation.
• The company's clinical trial results for NORSE TWO showed that ONS-5010/LYTENAVA met the primary and key secondary endpoints for efficacy, with a mean change of 11.2 letters in BCVA score compared to 5.8 letters with ranibizumab.
• The NORSE EIGHT trial, while not meeting its non-inferiority endpoint, demonstrated a mean +4.2 letter improvement in BCVA in the ONS-5010/LYTENAVA arm and +6.3 letter improvement in BCVA in the ranibizumab arm.

Management Changes

Legal Proceedings

• The company and certain of its officers have been named as defendants in a pending securities class action lawsuit.
• Certain of the company's officers and directors have also been named as defendants in a pending shareholder derivative action.

Related Party Transactions

• GMS Ventures, a significant stockholder, participated in a private placement of common stock and warrants.
• Syntone Ventures, LLC, a related party, participated in a private placement of common stock and warrants.

Stakeholder Impact

• Shareholders face the risk of dilution and potential losses due to the company's need for additional funding and the volatility of its stock price.
• Employees have been impacted by a recent workforce reduction.
• Customers (physicians and patients) may benefit from the potential availability of a lower-cost, approved bevacizumab option for retinal diseases.
• Suppliers and creditors may be affected by the company's financial challenges and potential restructuring.

Next Steps

• The company plans to resubmit the BLA application for ONS-5010/LYTENAVA in the first quarter of calendar 2025.
• The company anticipates commencing its initial commercial launches in the EEA and UK in the first half of calendar 2025.
• The company plans to develop ONS-5010/LYTENAVA for use in the treatment of other retina diseases such as DME and BRVO.

Key Dates

Keywords

ONS-5010/LYTENAVA, wet AMD, bevacizumab, retinal diseases, clinical trials, FDA, EMA, MHRA, regulatory approval, biopharmaceutical, commercialization, NORSE EIGHT, market exclusivity, data exclusivity